期刊文献+

胰腺癌组织中SUZ12蛋白的表达及临床意义 被引量:1

Expression of SUZ12 in pancreatic carcinoma and its significance
下载PDF
导出
摘要 目的分析SUZ12蛋白在胰腺癌组织中的异常表达及其与临床和病理特征的关系。方法对2002至2007年哈尔滨医科大学附属第一医院86例胰腺癌患者石蜡标本通过免疫组化方法检测SUZ12蛋白的表达情况。结果 SUZ12蛋白在63%的胰腺癌组织中表达增高,其增高与肿瘤的分化,淋巴结转移相关(P<0.001);此外,高表达的SUZ12蛋白对吉西他滨有抑制作用(P<0.05)。结论高表达的SUZ12蛋白促进肿瘤恶性生物学行为并能促使肿瘤细胞耐受吉西他滨。 Objective To examine a potential correlation of SUZ12 expression with clinico- pathological parameters and outcome in patients with pancreatic carcinoma. Methods The expression level of SUZ12 was determined by immunohistochemical analysis in 86 patients with pancreatic carcinoma from the First Affiliated Hospital of Harbin Medical University, from 2002 to 2007. Results High SUZ12 expression was found in 63% of pancreatic carcinomas and the over-expression was associated with tumor differentiation, lymph node metastasis (P 〈 0. 001 ) , furthermore, high SUZ12 expression inhibited the sensitivity of gemeitabine (P 〈 0. 05 ). Conclusion High SUZ12 expression promotes carcinogenesis and chemotherapeutic drugs resistance.
出处 《哈尔滨医科大学学报》 CAS 北大核心 2014年第2期133-136,共4页 Journal of Harbin Medical University
基金 哈尔滨市科技创新人才专项基金(2012RFXXS058)
关键词 胰腺癌 SUZ12 表观遗传学 吉西他滨 pancreatic carcinoma SUZ12 epigenetics gemcitabine
  • 相关文献

参考文献11

  • 1郑著家,李长福,韩继武.内镜超声引导下穿刺联合CFTR基因检测对慢性胰腺炎的诊断价值[J].哈尔滨医科大学学报,2011,45(3):266-268. 被引量:3
  • 2Chase A, Cross NC. Aberrations of EZH2 in cancer [ J]. Clin Cancer Res, 2011,17(9) :2613-2618.
  • 3Kirmizis A, Bartley SM, Farnham PJ. Identification of the poly- comb group protein SU(Z) 12 as a potential molecular target for hu- man cancer therapy[J]. Mol Cancer Ther, 2003,2(1 ) :113-12i.
  • 4Pizzatti L, Binato R, Cofre J, et al. SUZ12 is a candidate target of the non-canonical WNT pathway in the progression of chronic mye- loid leukemia[ J ]. Genes Chromosomes Cancer, 2010,49 ( 2 ) : 107-118.
  • 5Pasini D, Bracken AP, Jensen MR, et al. Suz12 is essential for mouse development and for EZH2 histone methyhransferase activity [J]. EMBO J, 2004,23(20) :4061-4071.
  • 6Murakami Y, Uemura K, Sudo T, et al. Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic ade- nocarcinoma [ J ]. Am J Surg, 2008,195 (6) :757-762.
  • 7Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial [ J ]. JAMA, 2007,297(3) :267-277.
  • 8Jung JW, Lee S, Seo MS, et al. Histone deacetylase controls a- dult stem cell aging by balancing the expression of polycomb genes and jumonji domain containing 3 [ J]. Cell Mol Life Sci, 2010,67 (7) :1165-1176.
  • 9Turgeon N, Blais M, Delabre JF, et al. The histone H3K27 meth- ylation mark regulates intestinal epithelial cell density-dependent proliferation and the inflammatory response [ J ]. J Cell Bioehem, 2013,114(5) :1203-1215.
  • 10McDermott KM, Zhang J, Hoist CR, et al. p16(INK4a) pre- vents centrosome d3,sfunction and genomic instability in primary cells[J]. PLoS Biol, 2006,4(3) :e51.

二级参考文献7

共引文献2

同被引文献2

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部